Abstract Number: 1204 • ACR Convergence 2022
An Increased Risk of Heart Failure and Heart Failure-Related Death Persists in Rheumatoid Arthritis: A National, Matched Cohort Study from 2000 to 2019
Background/Purpose: Rheumatoid arthritis (RA) predisposes patients to heart failure (HF), a leading cause of hospitalization in the US. While improvements in all-cause and cardiovascular (CVD)…Abstract Number: 1471 • ACR Convergence 2022
Trends and Predictors of Hospitalizations Due to Acute Myocardial Infarction in Systemic Lupus Erythematosus Patients
Background/Purpose: Cardiovascular events occur more frequently and with earlier onset in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies have concluded…Abstract Number: 1472 • ACR Convergence 2022
Autoantibodies Against Tripartite-Motif 72 Protein (TRIM72) in Systemic Lupus Erythematosus Patients and in a Lupus Mouse Models with Myocarditis, Can Compromise Membrane Repair in Cardiomyocytes Potentially Contributing to Cardiovascular Disease Progression
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that typically manifests in multiple organs, with some of the most significant complications occurring in the…Abstract Number: 1484 • ACR Convergence 2022
Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients
Background/Purpose: Lupus erythematosus (LE) patients are at heightened risk of clinical events, chiefly heart attacks and strokes, caused by ASCVD. To address this problem, we…Abstract Number: 1571 • ACR Convergence 2022
Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic autoimmune fibroinflammatory disease capable of affecting most organ systems. Large-vessel vasculitis is a well-described manifestation of the disease.…Abstract Number: 0284 • ACR Convergence 2022
Compared Mortality and Cardiovascular Safety of JAK Inhibitors and Tocilizumab in Patients with RA : A Systematic Review and Network Meta-analysis
Background/Purpose: The ORAL-Surveillance trial showed important data on the comparative safety between Tofacitinib and TNF inhibitors (TNFi) in the treatment of RA, leading to safety…Abstract Number: 1580 • ACR Convergence 2022
Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…Abstract Number: 0345 • ACR Convergence 2022
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…Abstract Number: 1596 • ACR Convergence 2022
The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at elevated cardiovascular risk. However, common risk calculators such as the atherosclerotic cardiovascular disease (ASCVD) risk estimator…Abstract Number: 0679 • ACR Convergence 2022
Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample
Background/Purpose: Antiphospholipid antibody syndrome (APLS) is strongly associated with the risk of cardiovascular events including acute coronary syndrome (ACS). However, there is limited data on…Abstract Number: 1623 • ACR Convergence 2022
Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis
Background/Purpose: Inflammatory dilated cardiomyopathy (iDCM) often leads to heart failure (HF), which is the main cause of cardiac mortality in patients with systemic autoimmune diseases.…Abstract Number: 0741 • ACR Convergence 2022
Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i, dapagliflozin, canagliflozin, and empagliflozin) are a class of oral hypoglycemic medication for management of Type II diabetes mellitus (T2D),…Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…Abstract Number: 0805 • ACR Convergence 2022
Rheumatic Fever and Streptococcal Cutaneous Infection: A Case-control Study in the Loyalty Islands, New Caledonia
Background/Purpose: Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) remain major public health problems in the South Pacific. Triggering by group A beta hemolytic…Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »